Leading the way in early detection of cognitive impairment
The First FDA cleared digital cognitive screening device
Cognivue’s® proprietary FDA-cleared technology is based on adaptive psychophysics. The technology collects 130,000 data points creating a unique patient experience customized to their individual visual and motor skills. This reliable test is validated against other recognized gold-standard cognitive assessment tools, while providing an experience custom to each patient. It is a self-administered computerized assessment which removes the bias that can be associated with more traditional cognitive assessment tools, standardizing your approach to testing.
Cognitive Assessment Devices
Cognivue offers two devices. First, an abbreviated cognitive screening device, the Cognivue Thrive® test detects potential cognitive impairment so that a patient can address modifiable risk factors to potentially change the course of the impairment. Second, a more comprehensive assessment device, the Cognivue Clarity® test provides more in-depth data points to supplement a full neurological assessment assisting the doctor in arriving at a differential diagnosis.
Cognivue Thrive® is a 5-minute cognitive performance screening tool for non-physicians
Cognivue Clarity® is a 10-minute assessment for physicians
Recommendations available to educate patients on evidence-based ways to manage lifestyle-related risk factors.
Cognivue Thrive® and Clarity® are indicated for use as adjunctive tools for evaluating cognitive function. They are not a stand-alone diagnostic tool and do not identify the presence or absence of clinical diagnoses. The device results are to be assessed and interpreted by a licensed clinician. Cognivue, Cognivue Thrive, Cognivue Clarity and Cogniwell are trademarks or registered trademarks of Cognivue, in the US and/or other countries. 2023 Cognivue. All rights reserved.